Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
A phase I trial of two sequence-specific schedules...
Journal article

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia

Abstract

This phase I trial evaluated two schedules of escalating vorinostat in combination with decitabine every 28 days: (i) sequential or (ii) concurrent. There were three dose-limiting toxicities: grade 3 fatigue and generalized muscle weakness on the sequential schedule (n = 1) and grade 3 fatigue on the concurrent schedule (n = 2). The maximum tolerated dose was not reached on both planned schedules. The overall response rate (ORR) was 23% (three …

Authors

How J; Minden MD; Brian L; Chen EX; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Webster S; Degelder T

Journal

Leukemia & Lymphoma, Vol. 56, No. 10, pp. 2793–2802

Publisher

Taylor & Francis

Publication Date

October 3, 2015

DOI

10.3109/10428194.2015.1018248

ISSN

1042-8194